MedTrace Logo

Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism

NCT07245927 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2025-11-24

No results posted yet for this study

Summary

The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.

Conditions

  • Pulmonary Embolism Acute Massive

Interventions

DRUG

Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®

Non-immunogenic staphylokinase 15 mg as a single intravenous bolus

Sponsors & Collaborators

  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

    collaborator OTHER_GOV

  • Supergene, LLC

    lead INDUSTRY

Principal Investigators

  • Sergei S. Markin, MD, Prof. · LLC "SuperGene"

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-10-31
Completion
2027-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07245927 on ClinicalTrials.gov